ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DEXILANT
Hyperacidity, GERD, and ulcers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DEXILANT Rx

Generic Name and Formulations:
Dexlansoprazole 30mg, 60mg; delayed-release caps.

Company:
Takeda Pharmaceuticals North America, Inc.

e-Prescribe this drug via Surescripts

Therapeutic Use:

Indications for DEXILANT:

Healing of all grades of erosive esophagitis (EE). Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). Maintenance of healing of EE and relief of heartburn.

Adult Dose for DEXILANT:

≥18yrs: Swallow whole, or sprinkle granules on 1 tablespoon of applesauce and swallow immediately. EE healing: 60mg once daily for up to 8 weeks. Maintenance of healed EE and relief of heartburn: 30mg once daily for up to 6 months. Symptomatic GERD: 30mg once daily for 4 weeks. Moderate hepatic impairment (Child-Pugh Class B): max 30mg/day.

Children's Dose for DEXILANT:

<18yrs: not established.

Pharmacological Class:

Proton pump inhibitor.

Warnings/Precautions:

Gastric malignancy. Use lowest dose for shortest duration appropriate to condition. If diarrhea occurs that does not improve, consider C. difficile diagnosis. Increased risk of osteoporosis-related fractures of the hip, wrist or spine with long-term and multiple daily dose PPI therapy. Severe hepatic impairment. Monitor magnesium levels with long-term therapy. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Concomitant atazanavir: not recommended (may decrease atazanavir levels). May alter absorption of pH-dependent drugs (eg, ketoconazole, digoxin, iron, ampicillin). Monitor warfarin. May increase tacrolimus, methotrexate levels.

Adverse Reactions:

Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, flatulence; rare: hypomagnesemia (w. prolonged PPI therapy).

Note:

Formerly marketed as Kapidex.

Metabolism:

Hepatic (CYP2C19, 3A4); 96.1–98.8% protein bound.

Elimination:

Renal, fecal

Generic Availability:

NO

How Supplied:

Caps—30, 90, 1000